Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 11Recurrence 5Leukemia 5Myelodysplastic Syndromes 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Erythroblastic, Acute 1Aortic aneurysm, familial thoracic 4 1

Interventions

Imatinib Mesylate 6Cytarabine 5ponatinib 4nilotinib 4venetoclax 3fludarabine phosphate 3Mycophenolic Acid 3thymoglobulin 2fludarabine 2enasidenib 2Methotrexate 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2Azacitidine 2Antilymphocyte Serum 2quizartinib 1methanesulfonic acid 1glasdegib 1etoposide phosphate 1daratumumab 1bosutinib 1asciminib 1Whole-Body Irradiation 1Transplantation 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid × quizartinib × Clear all
NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
24 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡